AstraZeneca (LON:AZN) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says

AstraZeneca (LON:AZN) had its price target hoisted by research analysts at Deutsche Bank Aktiengesellschaft from £117 to £120 in a note issued to investors on Friday, Digital Look reports. The brokerage presently has a “hold” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft‘s price objective points to a potential downside of 14.98% from the company’s current price.

Several other research analysts also recently issued reports on AZN. Citigroup upped their price target on shares of AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Royal Bank Of Canada began coverage on AstraZeneca in a report on Tuesday, September 8th. They set an “outperform” rating and a £145 price objective on the stock. Berenberg Bank restated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Wednesday, October 7th. Finally, Jefferies Financial Group restated a “buy” rating and set a £175 price objective on shares of AstraZeneca in a research report on Friday, October 30th. Six research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of £155.50.

AstraZeneca Price Performance

AstraZeneca stock traded up GBX 185.09 during mid-day trading on Friday, reaching £141.15. The company had a trading volume of 19,870,375 shares, compared to its average volume of 30,170,758. AstraZeneca has a fifty-two week low of £114.04 and a fifty-two week high of £157.32. The company has a current ratio of 1.01, a quick ratio of 0.59 and a debt-to-equity ratio of 66.10. The company has a market cap of £218.91 billion, a P/E ratio of 19.99, a P/E/G ratio of 0.86 and a beta of 0.21. The business has a fifty day simple moving average of £124.76 and a 200 day simple moving average of £134.29.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Michel Demare purchased 2,500 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was purchased at an average cost of £121.21 per share, for a total transaction of £303,025. Company insiders own 0.15% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.